Disfunción muscular esquelética de la EPOC. Mecanismos celulares

Archivos de Bronconeumologia

Volumn 37, Issue 4, 2001, Pages 197-205

  Agusti A G N ^a   Sauleda, J ^a   Morla M ^a   Miralles, C ^a   Busquets, X ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LEPTIN; MUSCLE PROTEIN; NITRIC OXIDE;

APOPTOSIS; ARTICLE; CACHEXIA; CELL HYPOXIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; GENETIC PREDISPOSITION; HUMAN; INFLAMMATION; LIFESTYLE; METABOLISM; MUSCLE CONTRACTION; NUTRITIONAL DISORDER; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; SKELETAL MUSCLE;

APOPTOSIS; CACHEXIA; CELL HYPOXIA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; LEPTIN; LIFE STYLE; LUNG DISEASES, OBSTRUCTIVE; MUSCLE CONTRACTION; MUSCLE PROTEINS; MUSCLE, SKELETAL; NITRIC OXIDE; NUTRITION DISORDERS; OXIDATIVE STRESS;

EID: 0347242367     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2896(01)75049-1     Document Type: Article

References (107)

1. Statement of the American Thoracic Society and European Respiratory Society. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. AJRCCM 1999; 159: S1-S40.
2. Schols AMWJ, Slangen J, Volovics L, Wouters EFM. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. AJRCCM 1998; 157: 1791-1797.
3. Cullen MI, Johnson MA, Mastaglia FL. Pathological reactions of skeletal muscle. En: Mastaglia FL, Lord Watson of Detchant, editores. Skeletal muscle pathology. Edimburgo: Churchill Livingstone, 1992; 123-184.
4. Jennekens FGI. Disuse, cachexia and aging. En: Mastaglia FL, Lord Walton of Detchant, editores. Skeletal muscle pathology. Edimburgo: Churchill Livingstone, 1992; 753-768.
5. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the utiquitin-proteasome pathway. N Engl J Med 1996; 335: 1897-1905.
6. Goldberg RM, Loprimzi CL. Cancer anorexia/cachexia. En: Von Gunten CF, editor. Palliative care and rehabilitation of cancer patients. Boston: Kluwer Academic Publishers, 1999; 31-41.
7. Emery PW. Cachexia in experimental models. Nutrition 1999; 15: 600-603.
8. Calles-Escandon J, Felig P. Fuel-hormone metabolism during exercise and after physical training. Clin Chest Med 1984; 5: 3-11.
9. DeVol DL, Rotwein P, Sadow JL, Novakofski J, Bechtel PJ. Activation of insuline-like growth factors gene expression during Work-induced skeletal muscle growth. Am J Physiol 1990, 259: E89-E95.
10. Kamischke A, Kemper DE, Castel MA, Luthke M, Rolf C, Behre H et al. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir R 1998; 11: 41-45.
11. Van Helder WP, Casey K, Goode RC, Radomski WM. Growth hormone regulation in two types of aerobic exercise of equal oxygen uptake. Eur J Appl Physiol 1986; 55: 236-239.
12. Van Helder WP, Casey K, Radomski WM. Regulation of growth hormone during exercise by oxigen demand and availability. Eur J Appl Physiol 1987; 56: 628-632.
13. Busquets X, Agustí AGN. La biología molecular en el diagnóstico y tratamiento de las enfermedades respiratorias. Arch Bronconeumol 1998; 34: 256-265.
14. Schumacker PT, Chandel N, Agustí AGN. Oxygen conformance of cellular respiration in hepatocytes. Am J Physiol 1993; 265: L395-L402.
15. Hochachka PW, Buck LT, Doll DJ Land SC Unifying theory of hypoxia tolerance: molecular metabolic defense and rescue mechanisms for suvrviving oxygen lack. Proc Natl Acad Sci USA 1996; 93: 9493-9498.
16. Hand SC. Quiescence in Artemia franciscana embryos: reversible arrest of metabolic and gene expression at low oxygen levels. J Exp Biol 1998; 201: 1233-1242.
17. Kroemer G, Reed JC: Mitochondrial control of cell death. Nature Med 2000; 6: 513-519.
18. Webb JS, Harrison DJ, Wyllie AH. Apoptosis: an overview of the process and its relevance in disease. En: Kaufmann SH, editor. Apoptosis. Pharmacological implications and therapeutic opportunities. San Diego: Academic Press, 1997; 1-34.
19. Sandri M, Carraro U, Podhorska-Okolov M, Rizzi C, Arslan P, Monti D et al. Apoptosis, DNA damage and uibitiquin expression in normal and mdx muscle fibers after exercise. FEBS Left 1995; 373: 291-295.
20. Meadows KA, Holly JM, Stewart CE. Tumor necrosis factor-alpha-induced apoptosis is associated with suppression of insulin-like growth factor binding protein-5 secretion in differentiating murine skeletal myoblasts. J Cell Physiol 2000; 183: 330-337.
21. Delpon E, Tamargo J. Fisiología del músculo. En: Tresguerras JAF, editor. Fisiología humana. Madrid: McGraw-Hill Interamericana, 1999; 14-35.
22. Agustí AGN, Cotes J, Wagner PD. Responses to exercise in lung diseases. Eur Respir Mon 1998; 6: 32-50.
23. Van Baak MA, Borghouts LB. Relationships with physical activity. Nutr Rev 2000; 58: S16-S18.
24. Brevetti G, Fanin M, De Amicis V, Carrozzo R, Di Lello F, Martone VD et al. Changes in skeletal muscle histology and metabolism in patients undergoing exercise deconditioning: effect of propionyl-L-carnitine. Mucle Nerve 1997; 20: 1115-1120.
25. Gibson JN, Halliday D, Morrison WL, Steward PJ, Hornsby GA, Watt PW et al. Decrease in human quadriceps muscle protein turnover consequent upon leg immobilization. Clin Sci 1987; 72; 503-509.
26. Kent-Braun JA, Ng AV, Young K. Skeletal muscle contractile and noncontractile components in young and older women and men. J Appl Physiol 2000; 88: 662-668.
27. Casaburi R, Patessio A, Ioli F, Zanaboni S, Donner CF, Wasserman K. Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease. Am Rev Respir Dis 1991; 143: 9-18.
28. Casaburi R, Porszazs J, Bums M, Caithers ER, Chang RSY, Cooper CB. Physiologic benefits of exercise training in rehabilitation of patients with severe chronic obstructive pulmonary disease. AJRCCM 1997; 155: 1541-1551.
29. 2 max. J Appl Physiol 1992; 73: 1067-1076.
30. Sala E, Roca J, Marrades RM, Alonso J, Gónzalez de Suso JM, Moreno A et al. Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease. AJRCCM 1999; 1726-1734.
31. Schols AMWJ, Soeters PB, Dingermans AMC, Mostert R, Frantzen PJ, Wouters EFM. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993; 147: 1151-1156.
32. Palmer RM, Thompson MG. Potential intracellular targets for anabolic/anticatabolic therapies. Curr Opin Clin Nutr Metab Care 1999; 2: 213-218.
33. Baarends EM, Schols AM, Westerterp KR, Wouters EF. Total daily energy expenditure. Relative to resting energy expenditure in clinically stable patients with COPD. Thorax 1997; 52: 780-785.
34. Schols AMW, Soeters PB, Mostert R, Saris WHM, Wouters EFM. Energy balance in chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 143: 1248-1252.
35. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS. Nutritional support for individuals with COPD: a meta-analysis. Chest 2000; 117: 672-678.
36. Sridhar MK. Why do patients with emphysema lose weigh? Lancet 1995; 345: 1190-1191.
37. Rennie NU, Edwards RH, Emery PW, Halliday D, Lundholm K, Millward DJ. Depressed protein synthesis is the dominant characteristics of muscle wasting and cachexia. Clin Physiol 1983; 3: 387-398.
38. Sieck GC, Johnson BB. Metabolic and structural alterations in skeletal muscle with hypoxia. En: Haddad G, Fister G. editores. Tissue oxygen respiration. Minessota: Marcel Dekker, 1996; 779-827.
39. Bigard AX, Sánchez H, Birot O, Serrurier B. Myosin heavy chain composition of skeletal muscle in young rats growing under hypobaric hypoxia conditions. J Appl Physiol 2000; 88: 479-486.
40. Green HJ, Sutton JR, Cymerman A, Young PM, Houston CS. Operation Everest II: adaptations in human skeletal muscle. J Appl Physiol 1989; 66: 2454-2461.
41. Bigard AX, Brunet A, Guezennec C-Y, Monod H. Skeletal mucle changes after endurance training at high altitude. J Appl Physiol 1991; 2114-2121.
42. Wuyam B, Payen JF, Levy P, Bensaidane H, Reutenauer H, Le Bas JF et al. Metabolism and aerobic capacity of skeletal muscle in chronic respiratory failure related to chronic obstructive pulmonary disease. Eur Respir J 1992; 5: 157-162.
43. Hughes RL, Katz H, Sahgal V, Campbell JA, Hartz R, Shields TW. Fiber size and energy metabolites in five separate muscle from patients with chronic obstructive lung disease. Respiration 1983; 44: 321-328.
44. Jakobsson P, Jorfeldt L, Brundin A. Skeletal muscle metabolites and fibre types in patients with advancec chronic obstructive pulmonary disease (COPD), with and without chronic respiratory. failure. Eur Respir J 1990; 3: 192-196.
45. Sauleda J, García-Palmer F, Wiesner RJ, Tarraga S, Harting I, Tomas P et al. Cytochrome oxidase activity and mitocondrial gene expression in skeletal muscle of patients with chronic obstructive pulmonary disease. AJRCCM 1998; 157: 1413-1417.
46. Calle EE, Thun NU, Petrelli JM, Rodríguez C, Heath CW. Bodymass index and mortality in a prospective cohort os U.S. adults. N Engl J Mod 1999; 341: 1097-1105.
47. Bessesen DH, Faggioni R. Recently identified peptides involved in the regulation of body weight. Semin Oncol 1998; 2: 28-32.
48. Casaburi R. Rationale for anabolic therapy to facilitate rehabilitation in obstructive pulmonary disease. Baillieres Clin Endocrinol Metabol 1998; 12: 871-880.
49. Van Heek M, Compton DS, France CF. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 1997; 99: 385-390.
50. Schols AM, Creutzberg EC, Buurman WA, Campfield LA. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. AJRCCM 1999; 160: 1220-1226.
51. Rosenbaum M, Leibel RL. The role of leptin in human physiology. N Engl J Med 1999; 341: 913-915.
52. Takabatake N, Nakamura H, Abe S, Hino T, Saito H, Yuki H et al. Circulating leptin in patients with chronic obstructive pulmonary disease. AJRCCM 1999; 159: 1215-1219.
53. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-280.
54. Agustí AGN, Noguera A, Sauleda J, Miralles C, Batle S, Busquets X. Systemic inflamation in chronic respiratory diseases. Eur Respir Mon 2000. En prensa.
55. Rahman I, MacNee W. Role of oxidants/antioxidants in smoking-induced lung diseases. Free Radic Biol Med 1996; 21: 669-681.
56. Schols AMWJ, Buurman WA, Staal-Van den Brekel AJ, Dentener MA, Wouters EFM. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 819-824.
57. Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary Disease. AJRCCM 1994; 150: 1453-1455.
58. Noguera A, Busquets X, Sauleda J, Villaverde JM, MacNee W, Agustí AGN. Altered expression of adhesion molecules and G-proteins in circulating neutrophils in COPD. AJRCCM 1998; 158: 1664-1668.
59. Sauleda J, García-Palmer FJ, González G, Palou A, Agustí AG. The activity of cytochrome oxidase is increased in circulating lymphocytes patients with chronic obstructive pulmonary disease, asthma, and chromic arthritis. AJRCCM 2000; 161: 32-35.
60. Espat NJ, Copeland EM, Moldawer LL. Tumor necrosis factor and cachexia: a current perspective. Surg Oncol 1994; 3: 255-262.
61. Ahmad S, Karlstad MD, Choudhry MA, Sayeed MM. Sepsis-induced myofibrillar protein catabolism in rat skeletal muscle. Life Sci 1994; 55: 1383-1391.
62. Li Y, Schwartz RJ, Waddell IA, Holloway BR, Raid MB. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-κB activation in response to tumor necrosis factor α. FASEB J 1998; 122: 871-880.
63. Medina R, Wing SS, Goldberg AC. Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy. Biochem J 1995; 307: 631-637.
64. Mitch WE, Medina R, Grieber S, May RC, England BK, Price SR et al. Metabolic acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes. J Clin Invest 1994; 93: 2127-2133.
65. Rahman I, Morrison D, Donaldson K, MacNee, W. Systemic oxidative stress in basthma, COPD, and smokers. AJRCCM 1996; 154: 1055-1060.
66. Rabinovich RA, Ardite E, Vilaró J, Capitán A, Fernández-Checa JC, Roca J. Limb muscle glutathione status after endurance training in COPD patients. AJRCCM 2000; 161: A753.
67. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. AJRCCM 1997; 156: 341-357.
68. Schulze-Osthoff K, Bakker AC, Vanhaesebroeck B, Beyaert R, Jacob WA, Fiers. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial function. Evidence for the involvement of mithocondrial radical generation. J Biol Chem 1992; 267: 5317-5323.
69. Jensen PK. Antimycin insensitive oxidation of succinate and NADPH in electron transport particles I. pH dependency and hydrogen peroxide formation. Biochim Biophys Acta 1966; 122: 157-166.
70. Reid MB, Haack Ke, Franchek KM, Valberg PA, Kobzik L, West MS. Reactive oxygen in skeletal muscle. I. Intracellular oxidant kinetics and fatigue in vitro. J Appl Physiol 1992; 73: 1797-1804.
71. Reid MB, Shoji T, Moody MR, Entman ML. Reactive oxygen in skeletal muscle II. Extraellular release of free radicals. J Appl Physiol 1992; 73: 1805-1809.
72. Sjodin B, Westing YH, Appel FS. Biochemical mechanims for oxygen free radical formation during exercise. Sports Med 1990; 10: 236-254.
73. Choudhury O, Sakaguchi S, Koyano K, Martin AFM, Muro H. Free radical injury in skeletal muscle ischemia and reperfusion. J Surg Res 1991; 1: 392-398.
74. Reikeras O, Ytrehus K. Oxygen radicals scavenger enzymes in ischaemia-reperfusion injury of skeletal muscle. Scand J Clin Lab Invest 1992; 52: 113-118.
75. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012.
76. Nakane M, Schmidt HH, Pollock JS, Forsterman U, Murad F. Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. FEBS Lett 1993; 316: 175-180.
77. Kobzik L, Reid MB, Bredt DS, Stamler JS. Nitric oxide in skeletal muscle. Nature 1994; 372: 546-548.
78. Frandsen U, López-Figueroa M, Hellsten Y. Localization of nitric oxide synthase in human skeletal muscle. Biochem Biophys Res Commun 1996; 227: 88-93.
79. Reid MB. Role of nitric oxide in skeletal muscle: synthesis, distribution and functional importance. Acta Physiol Scand 1998; 162: 401-409.
80. Miralles C, Busquets X, Santos C, Togores B, Hussain S, Rahman I. Regulation of iNOS expression and glutathione levels in rat liver by oxygen tension. FEBS Lett 2000; 476: 253-257.
81. Ji LL, Stratman FW, Lardy HA. Enzymatic down regulation with exercise in rat skeletal muscle. Arch Biochem Biophys 1988; 263: 137-149.
82. Whittom F, Jobin J, Simard P, Leblanc P, Simard C, Bernard S. Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Med Sci Sports Exerc 1998; 30: 1467-1474.
83. Gilbert HF. Biological disulfides: the third messenger? Modulation of phosphofructose kinase activity by the thiol/disulfide exchange. J Biol Chem 1982; 257: 12086-12091.
84. Solary M, Dubrez L, Eymin B. The role of apoptosis in the pathogenesis and treatment of diseases. Eur Respir J 1996; 9: 1293-1305.
85. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999; 27: 1230-1251.
86. Adams V, Jiang H, Yu J, Mobius-Winkler S, Fiehn E, Linke A et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol 1999; 33: 959-965.
87. Agustí AGN, Sauleda J, Batlle S, Miralles C, Gómez C, Togores B et al. Skeletal muscle apoptosis in COPD. Eur Respir J 2000; 16: 575.
88. Ebashi S, Endo M. Calcium ion and muscle contraction. Prog Biophys Mol Biol 1968; 18: 123-183.
89. Fiaccadori E, Coffrini E, Fracchia C, Rampulla C, Montagana T, Borghetti A. Hypophosphatemia and phosphorus depletion in respiratory and peripheral muscles of patients with respiratory failure due to COPD. Chest 1994; 105: 1392-1398.
90. Molloy DW, Dhingra S, Solven F, Willson A, McCarthy DS. Hypomagnesemia and respiratory muscle power. Am Rev Respir Dis 1984; 129: 497-198.
91. Brown RS. Potassium homeostasis and clinical implications. Am J Med 1984; 77: 3-9.
92. Cucina A, Sapienza P, Corvino V, Borrelli V, Mariani V, Randone B et al. Nicotine-induced smooth muscle cell proliferation is mediated through bFGF and TGF-beta 1. Surgery 2000; 127: 316-322.
93. Rincon J, Galuska D, Ryder JW, Kawano Y, Wallberg-Henriksson H, Gorrod JW et al. Effect of the nicotine metabolite 5'-hydroxycotidine on glucose transport and glycogen synthase activity in rat skeletal muscle. Pfügers Arch 1999; 439: 130-133.
94. Broal P. Main features of structure and function. En: Broal P, editor. The central nervous system. Estructure and function. Nueva York: Oxford University Press, 1992; 5-50.
95. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 1996; 334: 150-154.
96. Amoroso P, Wilson SR, Moxham J, Ponte J. Acute effects of inhaled salbutamol on the metabolic rate of normal subjects. Thorax 1993; 48: 882-885.
97. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle wealness in chronic airflow obstruction. AJRCCM 1994; 150: 11-16.
98. Nava S, Gayán-Ramírez G, Rollier H, Bisschop A, Dom R, De Bock V et al. Effects of acute steroid administration on ventilatory and peripheral muscles in rats. AJRCCM 1996; 153: 1888-1896.
99. Dekhuijzen PN, Gayán-Ramírez G, Bisschop A, de Bock V, Dom R, Decramer M. Corticosteroid treatment and nutritional deprivation cause a different pattern of atrophy in rat diaphragm. J Appl Physiol 1995; 78: 629-637.
100. Evans AB, Al-Himyari AJ, Hrovat MI, Pappagianopoulos P, Wain JC, Ginns LC et al. Abnormal skeletal muscle oxidative capacity after lung transplantation by P-MRS. AJRCCM 1997; 155: 615-621.
101. Hokanson JF, Mercier JR, Brooks GA. Cyclosporin A decreases rat skeletal muscle respiration in vitro. AJRCCM 1995; 151: 1849-1851.
102. Baier LJ, Permana PA, Yang X, Pratley RE, Hanson RL, Shen CQ et al. A calpain-10 gene polymorphism is assocaited with reduced muscle mRNA levels and insulin resistance. J Clin Invest 2000; 106: R69-R73.
103. Hribal ML, Federici M, Porezio O, Laura D, Bordoni P, Accili D et al. The Gly-Arg972 aminoacid polymorphism in insulin receptor substrate affects glucose metabolism in skeletal muscle cells. J Clin Endocrinol Metab 2000; 85: 2004-2013.
104. Williams AG, Rayson MP, Jubb M, World M, Woods DR, Hayward M et al. The ACE gene and muscle performance. Nature 2000; 403: 614.
105. Van Suylen RJ, Woulters EF, Pennigns HJ et al. The DD genotype of the anngiotensin converting enzyme gene is negatively associated with right ventricular hypertrophy in male patients with chronic obstructive pulmonary disease. AJRCCM 1999; 159: 1791-1795.
106. Guttridge DC, Mayo MW, Madrid LV et al. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289: 2363-2366.
107. Muscat GEO, Dressel U. Not a minute to waste. Nature Med 2000; 11: 1216-1217.